Article

Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice.

Department of Internal Medicine and The Institute of Hypertension, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Diabetes (Impact Factor: 8.47). 04/2010; 59(4):997-1005. DOI: 10.2337/db09-1241
Source: PubMed

ABSTRACT Accumulating evidence suggests that cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids (EETs), which play crucial and diverse roles in cardiovascular homeostasis. The anti-inflammatory, antihypertensive, and pro-proliferative effects of EETs suggest a possible beneficial role for EETs on insulin resistance and diabetes.
This study investigated the effects of CYP2J3 epoxygenase gene therapy on insulin resistance and blood pressure in diabetic db/db mice and in a model of fructose-induced hypertension and insulin resistance in rats.
CYP2J3 gene delivery in vivo increased EET generation, reduced blood pressure, and reversed insulin resistance as determined by plasma glucose levels, homeostasis model assessment insulin resistance index, and glucose tolerance test. Furthermore, CYP2J3 treatment prevented fructose-induced decreases in insulin receptor signaling and phosphorylation of AMP-activated protein kinases (AMPKs) in liver, muscle, heart, kidney, and aorta. Thus, overexpression of CYP2J3 protected against diabetes and insulin resistance in peripheral tissues through activation of insulin receptor and AMPK pathways.
These results highlight the beneficial roles of the CYP epoxygenase-EET system in diabetes and insulin resistance.

Download full-text

Full-text

Available from: Matthew L Edin, Mar 19, 2014
0 Followers
 · 
181 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluated the responses to soluble epoxide hydrolase (s-EH) inhibition, an essential enzyme in the metabolism of arachidonic acid, on food intake, body weight and metabolic parameters in mice fed a high fat-high fructose diet (HFD) for 10 weeks. After 5 weeks of HFD, mice were divided into two groups: 1) s-EH inhibitor (AR9281, 200mg/kg/day by gavage twice daily), and 2) vehicle (0.3ml per gavage). Food intake, body weight, oxygen consumption (VO(2)), carbon dioxide production (VCO(2)), respiratory quotient (RQ), and motor activity were measured weekly for more 5 weeks. HFD increased body weight (37±1 vs. 26±1g), and plasma of glucose (316±8 vs. 188±27mg/dl), insulin (62.1±8.1 vs. 15.5±5.0μU/ml), and leptin levels (39.4±3.6 vs. 7.5±0.1ng/ml) while reducing VO(2), VCO(2) and motor activity. s-EH inhibition for 5 weeks decreased caloric intake by ~32% and increased VO(2) by ~17% (42.8±1.4 vs. 50.2±1.5ml/kg/min) leading to significant weight loss. Inhibition of s-EHi also caused significant reductions in plasma leptin levels and visceral fat content. Uncoupling protein 1 (UCP1) content in brown adipose tissue was also elevated by ~50% during s-EH inhibition compared to vehicle treatment. These results suggest that s-EH inhibition with AR9281 promotes weight loss by reducing appetite and increasing metabolic rate, and that increased UCP1 content may contribute to the increase in energy expenditure.
    Nutrition, metabolism, and cardiovascular diseases: NMCD 12/2010; 22(7):598-604. DOI:10.1016/j.numecd.2010.10.017 · 3.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cytochrome P450 (CYP)-derived epoxides of arachidonic acid, i.e., the epoxyeicosatrienoic acids (EETs), are important lipid signaling molecules involved in the regulation of vascular tone and angiogenesis. Since many actions of 11,12-EET are dependent on the activation of protein kinase A (PKA), the existence of a cell surface Gs-coupled receptor has been postulated. To assess whether the responses of endothelial cells to 11,12-EET are enantiomer specific and linked to a potential G protein-coupled receptor, we assessed 11,12-EET-induced, PKA-dependent translocation of transient receptor potential (TRP) C6 channels as well as angiogenesis. In primary cultures of human endothelial cells, (±)-11,12-EET led to the rapid (30 seconds) translocation a TRPC6V5 fusion protein, an effect reproduced by 11(R),12(S)-EET, but not 11(S),12(R)-EET or (±)-14,15-EET. Similarly, endothelial cell migration and tube formation were stimulated by (±)-11,12-EET and 11(R),12(S)-EET while 11(S),12(R)-EET and 11,12-dihydroxyeicosatrienoic acid were without effect. The effects of (±)-11,12-EET on TRP channel translocation and angiogenesis were sensitive to EET antagonists and TRP channel trafficking was also prevented by a PKA inhibitor. The siRNA-mediated downregulation of Gs in endothelial cells had no significant effect on responses stimulated by VEGF or a PKA activator but abolished responses to (±)-11,12-EET. The down regulation of Gq/11 failed to prevent 11,12-EET-induced TRPC6 channel translocation or the formation of capillary like structures. Taken together, our results suggest that a Gs-coupled receptor in the endothelial cell membrane responds to 11(R),12(S)-EET, mediates the PKA-dependent translocation and activation of TRPC6 channels, as well as angiogenesis.
    Journal of Pharmacology and Experimental Therapeutics 04/2014; 350(1). DOI:10.1124/jpet.114.214254 · 3.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and Purpose: Epoxyeicosatrienoic acids (EETs), arachidonic acid-derived cytochrome P450 (CYP) epoxygenase metabolites, have diverse biological effects including anti-inflammatory properties in the vasculature. Increasing evidence suggests that inflammation in type 2 diabetes is a key component in the development of insulin resistance. Experimental Approach: In this study, we investigated if CYP epoxygenase expression and exogenous EETs can attenuate insulin resistance in diabetic db/db mice and in cultured hepatic cells (HepG2). In vivo, CYP2J2 expression and the accompanying increase in EETs attenuated insulin resistance as determined by plasma glucose levels, glucose tolerance test, insulin tolerance test, and hyperinsulinemic-euglycemic clamp studies. Key Results: CYP2J2 expression reduced the production of pro-inflammatory cytokines in liver, including CRP, IL-6, IL-1β and TNF-α, and decreased the infiltration of macrophages in liver. CYP2J2 expression also decreased activation of pro-inflammatory signaling cascades by decreasing NF-κB and MAPK activation in hepatocytes. Interestingly, CYP2J2 expression and exogenous EET treatment increased glucose uptake and activated the insulin signaling cascade both in vivo and in vitro, suggesting that CYP2J2 metabolites play a role in glucose homeostasis. Furthermore, CYP2J2 expression up-regulated PPARγ, which has been shown to induce adipogenesis that attenuate dyslipidemias observed in diabetes. Conclusions & Implications: All the findings suggest that CYP2J2 expression attenuates the diabetic phenotype and insulin resistance via inhibition of NF-κB and MAPK signaling pathways, and activation of PPARγ.
    AJP Endocrinology and Metabolism 11/2014; 308(4):ajpendo.00118.2014. DOI:10.1152/ajpendo.00118.2014 · 4.09 Impact Factor